Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

By sjmartinez • May 9, 2023

Frankiw L, Singh A, Peters C, Comin-Anduix B, Berent-Maoz B, Macabali M, Shammaie K, Quiros C, Kaplan-Lefko P, Baselga Carretero I, Ribas A, Nowicki TS. Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade. J Immunother Cancer. 2023 May;11(5):e006930. doi: 10.1136/jitc-2023-006930. PMID: 37156551.

Tags: Adoptive, Hematology/Oncology, immunotherapy, Investigational, nivolumab, Publications, sarcoma, Therapies, Tumor Escape

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial

Nikitas J, Ballas LK, Romero T, Lynch C, Ma TM, Valle LF, Sachdeva A, Chong N, Basehart V, Franco A, Reiter R, Saigal C, Chamie[...]

Depression and Inflammation in Women with Breast Cancer: Risk and Resilience Factors

Korecki JRT, Slavich GM, Ganz PA, Irwin MR, Cole S, Crespi CM, Bower JE. Depression and Inflammation in Women with Breast Cancer: Risk and Resilience[...]

Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer

Valle LF, Li J, Desai H, Hausler R, Haroldsen C, Chatwal M, Ojo M, Kelley MJ, Rebbeck TR, Rose BS, Rettig MB, Nickols NG, Garraway[...]